Fungal infections after hematopoietic stem cell transplantation.
Invasive fungal infections (IFIs) are associated with considerable morbidity and mortality after hematopoietic stem cell transplantation (HSCT). Despite that epidemiology of IFIs has changed notably by evolution in transplantation procedures as well as preventative strategies, the attributable mortality still remains high, mainly because of delayed initiation of treatment due to its diagnostic difficulty. Hence high-resolution computed tomography and non-culture based adjunctive diagnostic tests such as enzyme-linked immunosorbent assay for galactomannan and (1,3)-beta-D: -glucan have been incorporated into clinical practice, and global antifungal prophylaxis has been applied particularly to high-risk patients. Newer mold-active agents with higher efficacy and lower toxicity are currently being introduced as prophylaxis, and the combination of these agents are being evaluated as salvage therapy. This review summarizes recent advances in the diagnosis and management of IFIs in HSCT recipients. Further improvement of clinical outcome will be achieved by optimizing diagnostic, prophylactic and therapeutic approach based on individual patient's risk and situation.
Asano-Mori
Yuki
Y
Department of Hematology, Toranomon Hospital, Tokyo, Japan. yukia-tky@umin.ac.jp
D000935:Antifungal Agents / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000401:mortality*; D006801:Humans; D009181:Mycoses / Q000188:drug therapy / Q000401:mortality / Q000517:prevention & control; D012307:Risk Factors
D000935:Antifungal Agents